Meeting
2016 ASCO Annual Meeting
Phase II trial of eribulin for recurrent or metastatic salivary gland cancers.
Authors
Keith D. Eaton
University of Washington, Seattle, WA
Keith D. Eaton , Bernardo H. L. Goulart , Rafael Santana-Davila , Laura Quan Man Chow , Rebecca L. Wood , Cristina P. Rodriguez , Christina S. Baik , Renato G. Martins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT01613768
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6095)
DOI
10.1200/JCO.2016.34.15_suppl.6095
Abstract #
6095
Poster Bd #
417
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.
First Author: Youjin Kim
Poster
2020 ASCO Virtual Scientific Program
A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.
First Author: Wim van Boxtel
Poster
2016 ASCO Annual Meeting
PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).
First Author: Joel Guigay
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
First Author: Xiangrui Meng